Payment overview · 2025
General Payments
$326.18
13 reported records · 8 companies
Healthcare provider profile · identity verified
Joseph D. Drawdy, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · SALEM, KY · NPI 1164471926
Verified facts
What the public records show
CMS Open Payments records show Joseph D. Drawdy, APRN received $326.18 in general payments during 2025 across 13 reported records.
Novo Nordisk Inc accounted for 22.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $72.85 | 22.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $53.44 | 16.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $49.23 | 15.1% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $41.66 | 12.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $38.81 | 11.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.97 | 11.6% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.70 | 5.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.52 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $326.18 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $53.44 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $52.20 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $49.23 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $41.66 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $38.81 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.27 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $24.27 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 352 | 77 |
| Omeprazole | Omeprazole | 261 | 58 |
| Losartan Potassium | Losartan Potassium | 255 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 250 | 37 |
| Montelukast Sodium | Montelukast Sodium | 224 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 194 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 193 | 44 |
| Lisinopril | Lisinopril | 182 | 40 |
| Metformin Hcl | Metformin Hcl | 145 | 31 |
| Gabapentin | Gabapentin | 141 | 25 |
| Atenolol | Atenolol | 131 | 22 |
| Furosemide | Furosemide | 129 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 121 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 114 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 112 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 102 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 96 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 95 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 93 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 11 |
| Potassium Chloride | Potassium Chloride | 91 | 22 |
| Famotidine | Famotidine | 90 | 15 |
| Metformin Hcl Er | Metformin Hcl | 90 | 19 |
| Allopurinol | Allopurinol | 82 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 78 | 19 |
| Mupirocin | Mupirocin | 77 | 24 |
| Glimepiride | Glimepiride | 75 | 20 |
| Buspirone Hcl | Buspirone Hcl | 74 | 13 |
| Simvastatin | Simvastatin | 74 | 16 |
| Amoxicillin | Amoxicillin | 72 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 68 | 12 |
| Ezetimibe | Ezetimibe | 67 | 19 |
| Temazepam | Temazepam | 65 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 64 | 16 |
| Prednisone | Prednisone | 63 | 43 |
| Jardiance | Empagliflozin | 62 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 60 | 34 |
| Pregabalin | Pregabalin | 58 | suppressed |
| Carvedilol | Carvedilol | 55 | 14 |
| Meclizine Hcl | Meclizine Hcl | 55 | 13 |
| Sertraline Hcl | Sertraline Hcl | 55 | suppressed |
| Xarelto | Rivaroxaban | 53 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | 12 |
| Azithromycin | Azithromycin | 50 | 44 |
| Mirtazapine | Mirtazapine | 50 | suppressed |
| Januvia | Sitagliptin Phosphate | 49 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 12 |
| Tramadol Hcl | Tramadol Hcl | 48 | suppressed |
| Lorazepam | Lorazepam | 46 | 11 |
| Trazodone Hcl | Trazodone Hcl | 45 | 11 |
| Trulicity | Dulaglutide | 45 | suppressed |
| Eliquis | Apixaban | 44 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 18 |
| Naproxen | Naproxen | 43 | 18 |
| Risperidone | Risperidone | 43 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 39 | 11 |
| Meloxicam | Meloxicam | 39 | suppressed |
| Topiramate | Topiramate | 39 | suppressed |
| Vascepa | Icosapent Ethyl | 37 | suppressed |
| Celecoxib | Celecoxib | 36 | suppressed |
| Fenofibrate | Fenofibrate | 35 | suppressed |
| Ibuprofen | Ibuprofen | 35 | 11 |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Ozempic | Semaglutide | 33 | suppressed |
| Alprazolam | Alprazolam | 32 | suppressed |
| Nystatin | Nystatin | 32 | suppressed |
| Sucralfate | Sucralfate | 32 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 31 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Indapamide | Indapamide | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | 11 |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 18 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fluorouracil | Fluorouracil | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $326.18 · 13 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, Auvelity, CAPLYTA, COMIRNATY, FANAPT, HETLIOZ, NURTEC ODT, PREVNAR 20, QULIPTA, REXULTI, Wegovy, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error